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Atherosclerotic vascular disease is a major cause of premature 
morbidity and mortality throughout the world. Atherosclerosis 
begins to affect the arteries of many people in the second and third 
decades of life. Typically, however, the symptoms of 
atherosclerosis do not occur until several decades later. Despite 
this long time course and the prolonged period of clinical inactivity, 
the complications of atheroma such as myocardial infarction, 
unstable angina or stroke typically appear suddenly.
Atherosclerotic lesions not only lead to flow-limiting critical 
stenoses of the affected vessels, but may be complicated by 
thrombosis, resulting in ischaemic episodes. The platelets play a 
major role in this arterial throm botic process. Drugs that inhibit 
the platelet function have proved to be effective in preventing the 
clinical complications of atherothrombosis. The benefits and 
limitations of two important antiplatelet agents, aspirin and 
clopidogrel, are discussed.
6.l Characteristics of aspirin
Aspirin permanently inactivates the cyclooxygenase (COX) activity of 
prostaglandin (PG) H synthase-1 and PGH synthase-2, also referred 
to as COX-1 and COX-2. These isoenzymes catalyse the conversion 
of arachidonic acid to PGH2. PGH2 is the immediate precursor of 
PGD2, PGE2, PGF2a, PGI2 (prostacyclin) and TXA2 (thromboxane).
Aspirin exerts an inhibitory effect on platelet COX-1 that is 
approximately 50-100-fold more potent than that on monocyte 
COX-2. Aspirin induces a permanent defect in the TXA2-dependent 
platelet function. It is assumed to inactivate megakaryocytes too. 
Since approximately 10% of the platelet pool is exchanged each day, 
once-a-day dosing of aspirin is able to maintain an almost complete 
inhibition of platelet TXA2 production. The inhibition of COX-2- 
dependent pathophysiologic processes requires larger doses of 
aspirin because of the decreased sensitivity of COX-2 to aspirin. A 
much shorter dosing interval is also necessary because nucleated 
cells rapidly resynthesize the enzyme. Thus, there is an
approximately 100-fold difference in the daily dose of aspirin when 
it is used as an anti-inflammatory rather than as an antiplatelet 
agent.
Human platelets process PGH2 to produce TXA2, while vascular 
endothelial cells produce PGI2. TXA2 induces platelet aggregation 
and vasoconstriction, while PGI2 inhibits platelet aggregation and 
induces vasodilatation. TXA2 is largely a COX-1-derived product 
and is highly sensitive to aspirin inhibition. Vascular PGI2 can 
derive from both aspirin-sensitive COX-1 and largely aspirin- 
insensitive COX-2, which results in substantial residual COX-2- 
dependent PGI2 biosynthesis in vivo at doses of aspirin in the range 
30-100 mg.
Aspirin is rapidly absorbed in the stomach and upper intestine.
Peak plasma levels occur 30 to 40 min after ingestion and inhibition 
of the platelet function is evident by 1 h. The oral bioavailability of 
regular aspirin is approximately 40-50%. A considerably lower 
bioavailability has been reported for enteric coated tablets and 
microencapsulated preparations. Aspirin has a short half-life (15­
20 min) in the human circulation. Despite this rapid clearance, the 
platelet-inhibitory effect lasts for the life-span of the platelet 
because aspirin inactivates platelet COX-1 irreversibly. The mean 
life-span of human platelets is approximately 10 days.
The main side-effects of aspirin include gastric ulcers, renal failure 
and haemorrhagic complications.
6.2 Characteristics of clopidogrel
Clopidogrel selectively inhibits the binding of adenosine 
diphosphate (ADP) to its platelet receptor, and the subsequent ADP- 
mediated activation of the glycoprotein GPIIb/IIIa complex, thereby 
inhibiting platelet aggregation. The hepatic biotransformation of 
clopidogrel to an active metabolite is necessary to induce the 
inhibition of platelet aggregation. Clopidogrel also inhibits platelet 
aggregation induced by agonists other than ADP by blocking the 
amplification of platelet activation by released ADP. Clopidogrel 
acts by irreversibly modifying the platelet ADP receptor. 
Consequently, platelets exposed to clopidogrel are affected for the 
remainder of their life-span. This justifies a once-daily regimen of 
clopidogrel.
Clopidogrel is rapidly absorbed after oral administration, with peak 
plasm a levels of the main circulating metabolite occurring 
approximately 1 h after dosing. Clopidogrel is extensively 
metabolized by the liver. The dose-dependent inhibition of platelet 
aggregation can be detected 2 h after a single oral dose of 
clopidogrel. Repeated doses of 75 mg clopidogrel per day inhibit 
ADP-induced platelet aggregation on the first day, and the inhibition 
reaches a steady state between day 3 and day 7. The platelet 
aggregation and the bleeding time gradually return  to the baseline 
values after treatm ent is discontinued, generally in about 5 days.
The elimination half-life of the main circulating metabolite after 
either single or repeated administration is 8 h.
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Clopidogrel treatm ent leads to fewer gastrointestinal bleeding 
complications than those observed with aspirin.
6.3 Clinical trials
A meta-analysis of 287 randomized antiplatelet trials by the 
Antithrombotic Trialists' Collaboration documented that 
antiplatelet therapy reduced the overall risk of serious vascular 
events in high-risk patients by 22% as compared with the controls. 
Antiplatelet therapy is effective for patients with acute myocardial 
infarction, stable or unstable angina, stroke, transient ischaemic 
attack, and intermittent claudication. The meta-analysis concluded 
that daily aspirin doses of 75-150 mg seem to be as effective as 
higher doses for long-term treatm ent.
The results of the CAPRIE study indicated that the long-term 
administration of clopidogrel to patients with atherosclerotic 
vascular disease leads to a significant, 8.7% relative reduction in the 
risk of vascular events as compared with aspirin treatm ent. The 
overall safety profile of clopidogrel was at least as good as that of 
medium-dose aspirin. The recommended daily dose of clopidogrel 
is usually 75 mg.
The synergistic antiplatelet effect produced by using clopidogrel on 
top of aspirin may be beneficial in high-risk patients. The CURE 
study dem onstrated that long-term treatm ent with clopidogrel in 
addition to standard therapy including aspirin was superior to the 
standard therapy alone in the prevention of major vascular 
ischaemic events in patients with unstable angina or non-Q-wave 
myocardial infarction. However, the risk of major bleeding among 
patients receiving this combined antiplatelet treatm ent was found to 
be increased.
6.4 Aspirin resistance
Aspirin fails to prevent approximately 80% of recurrent vascular 
events among high-risk patients. There are several reasons why 
aspirin may not be totally effective in preventing recurrent serious 
vascular events. One possible explanation is that some patients are 
resistant to the antiplatelet effects of aspirin. Other possible 
reasons include an incorrect diagnosis, non-compliance with the 
medication, drug interactions or an insufficient dose.
The term  "aspirin resistance" has evolved to describe the failure of 
aspirin to produce the expected response as concerns one or more 
laboratory measures of platelet activation and aggregation. It has 
been estimated that therapy with aspirin does not result in adequate 
antiplatelet efficacy in 5-40% of patients with vascular disease.
There are various techniques with which to measure platelet 
aggregation, including optical platelet aggregometry, whole-blood 
aggregometry, and determination of the platelet aggregate ratio 
and platelet reactivity index. The PFA-100 is a semiautomated 
platelet function analyser which allows a rapid assessm ent of 
platelet adhesion/aggregation. The urinary 11-dehydro­
thromboxane B2 level may also be used as a measure of the 
antiplatelet effects of aspirin.
Previous studies have revealed that cerebrovascular and 
cardiovascular patients found by laboratory tests to be aspirin- 
resistant are at an increased risk of major vascular events. In one of 
their recent publications, Eikelboom et al. defined aspirin resistance 
as a failure to suppress thromboxane generation. They measured 
the levels of urinary 11-dehydro-thromboxane B2, a marker of in 
vivo thromboxane generation, in cases treated with aspirin who had 
vascular events during a 5-year follow-up period, and in age- and
sex-matched controls who also received aspirin, but who did not 
undergo such an event. It was concluded that, in aspirin-treated 
patients, the urinary concentrations of 11-dehydro-thromboxane 
B2, a possible marker of aspirin resistance, predict the future risk 
of myocardial infarction or cardiovascular death. Gum et al. defined 
aspirin resistance on the basis of optical platelet aggregation 
testing. Aspirin resistance was associated with increased risks of 
death, myocardial infarction and cerebrovascular events as 
compared with patients who were aspirin-sensitive.
The results of several relatively small studies of stroke patients 
have suggested that larger doses may be more effective than lower 
doses in limiting laboratory aspirin resistance. However, a much 
larger database failed to substantiate a dose-dependent effect of 
aspirin in stroke prevention. Platelet aggregation, as measured by 
conventional methods ex vivo, may display limited sensitivity to the 
in vivo effect of aspirin.
6.5 Clopidogrel resistance
Although clopidogrel has been associated with a lower rate of 
ischaemic episodes than that observed with aspirin, it still fails to 
prevent a significant proportion of vascular events. Furthermore, 
platelet aggregation studies have revealed an increasing body of 
evidence of the existence of non-responsiveness to clopidogrel. 
However, little is known as yet about the prevalence and clinical 
relevance of clopidogrel resistance.
6.6 Clinical decision-making
With regard to the management of patients with aspirin resistance, 
an increase in the dose of aspirin, followed by repeat testing or 
conversion to clopidogrel or clopidogrel plus aspirin, might be 
beneficial. When the aspirin dose is increased, it should be taken 
into consideration that low-dose aspirin (81 or 325 mg/day) was 
associated with lower risks of stroke, MI or death as compared with 
high-dose regimens (650 o r 1300 mg/day) in a large group of 
patients undergoing carotid endarterectomy. Little is known about 
the clinical relevance of clopidogrel resistance determined by 
laboratory tests.
A uniformly applied antiplatelet regime based on the overall results 
of clinical trials might not be the best treatm ent option for every 
patient. Platelet function tests may help individualize treatment. 
Platelet function tests preceding any kind of antiplatelet treatm ent 
may provide useful baseline information for further monitoring.
In summary, both the mechanisms and the clinical relevance of 
aspirin and clopidogrel resistance need to be investigated further. 
Appropriate platelet function tests may become useful tools in the 
future for selection of the best antiplatelet therapy for an individual 
patient. However, none of the currently available laboratory tests 
for measurem ent of the antiplatelet effect of aspirin or clopidogrel 
have been demonstrated to be specific, accurate or reproducible 
enough. Additional work is required to standardize and validate 
laboratory tests of the antiplatelet effects of aspirin and 
clopidogrel. In the meantime, clinicians should ensure the 
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